

Provided by:



## Acute Leukemia and Myeloid Neoplasms Case Conference 2018-2020

### Acute Leukemia and Myeloid Neoplasms Case Conference 2018-2020

August 12, 2020

12:00 PM - 1:00 PM

Blue Jeans

#### Target Audience

This program has been designed for Internal Medicine - Hematology, Internal Medicine - Medical Oncology, Pathology - Anatomic

#### Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Review the technique, ordering and interpretation of the appropriate bone marrow and blood studies for new patients
- 2 Know the standard of care treatment for patients with acute leukemia
- 3 Identify appropriate clinical trials to increase the number of patients enrolled
- 4 Evaluation of molecular (CPD) data in the context of clinical and pathologic data

#### Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

#### Designation of Credit

**Physicians:** Penn Medicine designates this live activity for a maximum of **1.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is for **1.00** contact hours.

**Pharmacists:** This activity is approved for **1.00** contact hours  
UAN Number: JA0000324-0000-20-002-L04-P

**PAs:** AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

**Approved for (PSRM) patient safety/risk management designation**

#### Acknowledgement of Commercial Support\*

None

For more information, please contact  
Cherylann Lane, Olivia Hollister  
(215) 662-3181, (215) 954-3631

cherylann.lane@uphs.upenn.edu, Olivia.Hollister@pennmedicine.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose, we consider relationships of the person involved to include financial relationships of a spouse or partner.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. Any peer reviewer with a potential conflict of interest will recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of commercial interest/Nature of relationship
Alison Loren, MD, MSCE	Co-Director	Nothing to disclose
Keith Pratz, MD	Co-Director, Faculty	Advisor or Review Panel Member-Abbvie-Oncology   Advisor or Review Panel Member-Celgene-oncology  Advisor or Review Panel Member-Agios-Oncology  Advisor or Review Panel Member-Jazz Pharmaceuticals-Oncology  Advisor or Review Panel Member-Astellas-Oncology
Selina M. Luger , MD	Course Director	Advisor or Review Panel Member-Bristol-Myers Squibb-New drugs  Advisor or Review Panel Member-jazz-AML therapy  Advisor or Review Panel Member-loxo-AML therapy  Advisor or Review Panel Member-Agios-targeted therapy  Grants/Research Support Recipient-Celgene-MDS  Grants/Research Support Recipient-Oyclacel-MDS/AML  Grants/Research Support Recipient-Onconova-MDS  Grants/Research Support Recipient-Roche-AML  Grants/Research Support Recipient-Kura-CMML/AML/MDS/MPN  Grants/Research Support Recipient-Ariad-CML
Colleen Kucharczuk, DNP	Nurse Planner	Nothing to disclose
Noelle Frey, MD	Other Planning Committee Member	Husband Employer-Merck and Company, Inc.- Infectious Disease  Consultant-Novartis AG-Oncology
Elizabeth Hexner, MD	Other Planning Committee	Grants/Research Support Recipient-Blueprint

	Member	Medicines Advisor or Review Panel Member-Blueprint Medicines Exam committee member-American Board of Internal Medicine
Jennifer Jd. Morrisette, PhD	Other Planning Committee Member	Consultant-Novartis AG-N/A Consultant-BioRad-NA Stock Shareholder (excluding mutual funds)-ThermoFisher
Alexander Perl, MD	Other Planning Committee Member	Consultant-Daiichi Sankyo Consultant-Astellas Consultant-Arog Consultant-Abbvie Advisor or Review Panel Member-NewLink Genetics Consultant-Forma Therapeutics Consultant-Actinium Pharmaceuticals DSMB member for trial-Leukemia and Lymphoma Society Grants/Research Support Recipient-Astellas Grants/Research Support Recipient-Abbvie Grants/Research Support Recipient-Bayer Corporation Grants/Research Support Recipient-FujiFilm Grants/Research Support Recipient-Daiichi Sankyo
Craig Freyer, PharmD	Pharmacy Planner	Nothing to disclose

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected